AIM ImmunoTech Inc.
AIM · AMEX
Bulios Fair Price
$0.2
6.5% upside
Current Price
$0.19
According to Bulios Fair Price, AIM is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
AIM ImmunoTech Inc. (AIM) is a biotechnology company focused on the research and development of immunotherapeutic drugs and treatment approaches. The company specializes in developing drugs that influence the immune system of patients to combat various diseases, including cancer and infectious diseases. AIM ImmunoTech focuses on utilizing the immune system to enhance the body's defenses and support immune responses against diseases. The company is actively engaged in scientific research and clinical trials to verify the effectiveness and safety of its drugs and approaches. Their goal is to bring new immunotherapeutic treatment options to the market that can bring improvements for patients with various diseases. AIM ImmunoTech Inc. (AIM) shares may be an attractive investment opportunity for investors interested in the biotechnology sector and seeking an investment in a company focused on innovative treatment approaches through immunotherapy.
Sector
Healthcare
Industry
Biotechnology
CEO
Thomas K. Equels
Employees
19
Headquarters
Ocala
Upcoming events
Earnings
Upcoming earnings report